Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Condition:   Urinary Bladder Neoplasms Interventions:   Drug: Pembrolizumab;   Radiation: Conventional Radiotherapy (Bladder only);   Radiation: Conventional Radiotherapy (Bladder and pelvic nodes);   Radiation: Hypofractionated Radiotherapy (Bladder only);   Drug: Cisplatin;   Drug: Fluorouracil (5-FU);   Drug: Mitomycin C (MMC);   Dru g: Gemcitabine;   Drug: Placebo to Pembrolizumab Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials